All In Biotech

Drug Trial Radar · NCT07190430

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

A Phase 1, Open-label, Fixed Sequence Study to Evaluate The Effect of Steady-State Dosing of PF-08049820 on the Single Dose Pharmacokinetics of Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Oct 3, 2025

Primary completion

Dec 15, 2025

Study completion Dec 15, 2025

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to see how a medicine called PF-08049820 affects how other medicines move through the body. This information will help plan future studies. The other medicines include: * Birth control pills (containing ethinyl estradiol and levonorgestrel) * Midazolam (used to help people relax or sleep) * Dabigatran etexilate (used to prevent blood clots) This study is seeking participants who: * are female and are 18 years or older * weigh more than 110 pounds (50 kg) * have a healthy body weight (not too low or too high) * are generally healthy with no serious medical problems. People with serious health problems, recent medicine use, or who had certain vaccines recently cannot join. * are willing to follow all the study rules The study has 6 parts, and each part happens one after the other. In the first 3 parts, participants take just one dose of each medicine (midazolam, dabigatran, and birth control pills) to see how these medicines work alone. In the last 3 parts, they take PF-08049820 twice a day, along with one of the other medicines, to see how PF-08049820 changes the way those medicines move through the body. The whole study will take about 12 to13 weeks and participants will stay overnight in the clinic for about 25 days.

Conditions

  • Atopic Dermatitis

Interventions

  • PF-08049820Drug

    Administered orally

  • MidazolamDrug

    Administered orally

  • Dabigatran EtexilateDrug

    Administered orally

  • Portia (EE and LN) or equivalent oral tabletDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK): Area Under the curve (AUC) of MidazolamTime frame: From pre-dose up to 24 hours post dose in Periods 1 and 4
  2. PK: Plasma Maximum Concentration (Cmax) of MidazolamTime frame: From pre-dose up to 24 hours post dose in Periods 1 and 4
  3. PK: Area Under the curve (AUC) of dabigatranTime frame: From pre-dose up to 48 hours post dose in Periods 2 and 5
  4. PK: Cmax of dabigatranTime frame: From pre-dose up to 48 hours post dose in Periods 2 and 5
  5. PK: AUC of Ethinyl estradiol and levonorgestrelTime frame: From pre-dose up to 96 hours post dose in Periods 3 and 6
  6. PK: Cmax of Ethinyl estradiol and levonorgestrelTime frame: From pre-dose up to 96 hours post dose in Periods 3 and 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pfizer Clinical Research Unit - New Haven

    New Haven, Connecticut

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.